Steris PLC (STE) Given Average Rating of “Buy” by Analysts

Shares of Steris PLC (NYSE:STE) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $72.33.

STE has been the subject of a number of research reports. KeyCorp restated an “overweight” rating and set a $101.00 target price (up from $91.00) on shares of Steris in a report on Thursday, November 2nd. Zacks Investment Research cut shares of Steris from a “buy” rating to a “sell” rating in a report on Monday, November 6th. TD Securities raised their target price on shares of Steris from C$14.00 to C$16.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. Finally, Raymond James Financial raised their target price on shares of Steris from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, October 16th.

Steris (NYSE STE) opened at $88.33 on Thursday. Steris has a 12 month low of $65.26 and a 12 month high of $93.39. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48. The company has a market cap of $7,540.00, a P/E ratio of 52.58 and a beta of 1.27.

Steris (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $0.94 EPS for the quarter, missing the Zacks’ consensus estimate of $0.95 by ($0.01). The company had revenue of $634.20 million for the quarter, compared to analyst estimates of $629.02 million. Steris had a net margin of 5.59% and a return on equity of 11.49%. Steris’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.89 EPS. research analysts expect that Steris will post 4.06 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 20th. Investors of record on Wednesday, November 22nd were issued a dividend of $0.31 per share. This represents a $1.24 dividend on an annualized basis and a yield of 1.40%. The ex-dividend date was Tuesday, November 21st. Steris’s payout ratio is 73.81%.

In related news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $90.50, for a total value of $905,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP John Adam Zangerle sold 3,650 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total transaction of $321,200.00. The disclosure for this sale can be found here. Insiders have sold 36,650 shares of company stock valued at $3,315,200 over the last 90 days. 2.55% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the stock. Zions Bancorporation acquired a new stake in shares of Steris during the 3rd quarter valued at $178,000. Citigroup Inc. acquired a new stake in shares of Steris during the 2nd quarter valued at $206,000. BT Investment Management Ltd acquired a new stake in shares of Steris during the 2nd quarter valued at $210,000. GSA Capital Partners LLP acquired a new stake in shares of Steris during the 3rd quarter valued at $284,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Steris by 10.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,276 shares of the medical equipment provider’s stock valued at $267,000 after buying an additional 311 shares during the period. 89.40% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Steris PLC (STE) Given Average Rating of “Buy” by Analysts” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/12/steris-plc-ste-given-average-rating-of-buy-by-analysts.html.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply